Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Francisca Sosa-Jurado is active.

Publication


Featured researches published by Francisca Sosa-Jurado.


Journal of Infection | 2008

Prevalence of hepatitis C virus in the Mexican population: A systematic review

Francisca Sosa-Jurado; Verónica Vallejo-Ruiz; Daniel Meléndez-Mena; Julio Reyes-Leyva

BACKGROUND Although hepatitis C virus (HCV) infection is considered a relevant public health problem in Mexico, the prevalence is still under discussion. The objective of this study was to conduct a systematic review to explore the prevalence of HCV infection in the Mexican population. METHODS A systematic review of studies reporting prevalence in Mexican population was performed using several free-access databases. RESULTS Sixty-eight works fulfilled the search criteria. From these, 44 studies involved asymptomatic subjects and 28 involved patients or high-risk subjects. Prevalence of blood donors (6,955,558 persons) ranged from 0.0% to 2.05%, with 7/32 studies reporting values >1%, whereas prevalence of non-donor asymptomatic subjects (28,528 persons) from 0.0% to 2.7%, with 7/11 studies reporting values >1%, and medical personnel from 0.0% to 2.08% (1,227 persons), with 4/11 studies reporting values >1%. Prevalence of patients with chronic hepatic disease ranged from 6.7% to 77%. The most prevalent genotype was 1 (30.0-87.5%), of which subtype 1b is the most frequent (11.9-61.9%). The main risk factors were blood transfusion and unprotected sex or having multiple sex partners. CONCLUSIONS The prevalence in the Mexican population seems to be in accordance with that previously estimated by the World Health Organization (1-2.5%).


Salud Publica De Mexico | 2004

Factores bióticos y abióticos que determinan la seroprevalencia de anticuerpos contra Trypanosoma Cruzi en el municipio de Palmar de Bravo, Puebla, México

Francisca Sosa-Jurado; José Lino Zumaquero-Ríos; Pedro A. Reyes; Abel Cruz-García; Carmen Guzmán-Bracho; Víctor M Monteón

Objective. To establish the relationship between seroprevalence for antibodies against Trypanosoma cruzi and its relationship with biotic and abiotic factors. Material and Methods. A cross-sectional study was conducted between August 2000 and September 2001. The study population consisted of a simple random sample of 390 volunteers residing in Palmar de Bravo, Puebla, Mexico. Sample and data collection procedures included assaying antibodies against T cruzi with validated assays, and searching for domestic reservoirs and triatomine bugs. The relationship between biotic and abiotic factors with seropositivity was assessed. Statistical analysis was conducted using Kappa values for diagnostic tests; statistical significance was assessed with 2 x 2 tables, chi-squared test with Yates’ correction, Fisher exact test, and odds ratios. Results. The seroprevalence of T cruzi infection in humans was 4%; in domestic reservoirs (horses, pigs, and dogs) only 10% of canine reservoirs were positive. Vector species recognized were T barberi and T pallidipennis, with a Dispersion Area Index and a Colonization Index of 55% and 40%, respectively. The most important risk factors associated with positive serology were altitude


Memorias Do Instituto Oswaldo Cruz | 2003

Electrocardiographic findings in Mexican chagasic subjects living in high and low endemic regions of Trypanosoma cruzi infection

Francisca Sosa-Jurado; Miguel Mazariego-Aranda; Nidia Hernández-Becerril; Verónica Garza Murillo; Manuel Cárdenas; Pedro A. Reyes; Kenji Hirayama; Víctor M Monteón

In México the first human chronic chagasic case was recognized in 1940. In spite of an increasing number of cases detected since that time, Chagas disease in México has been poorly documented. In the present work we studied 617 volunteers subjects living in high and low endemic regions of Trypanosoma cruzi infection with seroprevalence of 22% and 4% respectively. Hemoculture performed in those seropositive subjects failed to demonstrate circulating parasites, however polymerase chain reaction identified up to 60% of them as positives. A higher level of anti-T. cruzi antibodies was observed in seropositive residents in high endemic region, in spite of similar parasite persistence (p < 0.05). On standard 12 leads electrocardiogram (ECG) 20% to 22% seropositive individuals from either region showed right bundle branch block or ventricular extrasystoles which were more prevalent in seropositive than in seronegative individuals (p < 0.05). In conclusion, the frequency or type of ECG abnormality was influenced by serologic status but not by endemicity or parasite persistence. Furthermore, Mexican indeterminate patients have a similar ECG pattern to those reported in South America.


Virology Journal | 2010

Hepatitis C virus infection in blood donors from the state of Puebla, Mexico

Francisca Sosa-Jurado; Belinda Guzmán-Flores; Julia I Ruiz-Conde; Daniel Meléndez-Mena; Martín T Vargas-Maldonado; Ygnacio Martínez-Laguna; Laura Contreras-Mioni; Verónica Vallejo-Ruiz; Julio Reyes-Leyva

BackgroundWorldwide, 130 million persons are estimated to be infected with HCV. Puebla is the Mexican state with the highest mortality due to hepatic cirrhosis. Therefore, it is imperative to obtain epidemiological data on HCV infection in asymptomatic people of this region. The objective of present study was to analyze the prevalence of antibodies and genotypes of hepatitis C virus (HCV) in blood donors from Puebla, Mexico.ResultsThe overall prevalence was 0.84% (515/61553). Distribution by region was: North, 0.86% (54/6270); Southeast, 1.04% (75/7197); Southwest, 0.93% (36/3852); and Central, 0.79% (350/44234). Ninety-six donors were enrolled for detection and genotyping of virus, from which 37 (38.5%) were HCV-RNA positive. Detected subtypes were: 1a (40.5%), 1b (27.0%), mixed 1a/1b (18.9%), undetermined genotype 1 (5.4%), 2a (2.7%), 2b (2.7%), and mixed 1a/2a (2.7%). All recovered donors with S/CO > 39 were HCV-RNA positive (11/11) and presented elevated ALT; in donors with S/CO < 39 HCV-RNA, positivity was of 30.4%; and 70% had normal values of ALT. The main risk factors associated with HCV infection were blood transfusion and surgery.ConclusionsHCV prevalence of donors in Puebla is similar to other Mexican states. The most prevalent genotype is 1, of which subtype 1a is the most frequent.


Journal of Neuroimmunology | 2014

Quantitative analysis of the suppressors of cytokine signaling 1 and 3 in peripheral blood leukocytes of patients with multiple sclerosis

Virginia Sedeño-Monge; Raúl Arcega-Revilla; Emmanuel Rojas-Morales; Juan Carlos Pérez-García; Francisca Sosa-Jurado; Verónica Vallejo-Ruiz; Casandra Lucrecia Solis-Morales; Salvador Aguilar-Rosas; Julio Reyes-Leyva

Multiple sclerosis (MS) is an autoimmune disease characterized by a triad of inflammation, demyelination and gliosis. Because the suppressors of cytokine signaling (Socs) regulate the immune response, we quantified SOCS1 and SOCS3 transcription in peripheral blood leukocytes of patients with MS. SOCS1 transcription decreased significantly in MS patients compared with neurologically healthy persons (0.08±0.02 vs. 1.02±0.23; p=0.0001); while SOCS3 transcription increased in MS patients compared with controls (2.76±0.66 vs. 1.03±0.27; p=0.0008). Our results showed an imbalance of SOCS1 and SOCS3 transcription in MS patients, and a moderated negative correlation between them (Spearmans r=-0.57; p=0.0003).


Salud Publica De Mexico | 2005

Distribución heterogénea de la prevalencia de anticuerpos contra Trypanosoma cruzi en donadores de sangre en Puebla, México

Víctor M Monteón; Pedro A Reyes-López; Adalid Sosa-Palacio; Gloria León-Tello; Jaime Martínez-Murguía; Francisca Sosa-Jurado

Objective. To determine the seroprevalence and associated factors, of antibodies against Trypanosoma cruzi (T. cruzi Ab) among blood donors living in rural and suburban areas and risk regions. Material and Methods. A cross-sectional study was conducted from January to December 2003, in 2489 blood donors of seven regions of Puebla, who were evaluated for mandatory viral and T. cruzi serological tests using validated procedures Results. The seroprevalence for T. cruzi Ab was 1.24% (31/2489), similar to hepatitis C (HVC) (1.5%) and higher than human immunodeficiency virus (HIV) (0.4%) and hepatitis B (HVB) (0.3%). The highest seroprevalences were observed in the regions of Tehuacan-Sierra Negra and Mixteca, up to 2.6%, while in Sierra nororiental and Angelopolis no positive blood donors were identified. A positive association was observed between seropositivity and being older than forty years and being born and raised in Tehuacan-Sierra Negra and Mixteca. Conclusions. T.cruzi seroprevalence distribution is heterogeneous, from 0% to 2.6%, with higher seroprevalences in the regions of Tehuacan-Sierra Negra and Mixteca.


Hepatitis Monthly | 2016

Prevalence of Serologic Hepatitis B Markers in Blood Donors From Puebla, Mexico: The Association of Relatively High Levels of Anti-Core Antibodies With the Detection of Surface Antigen and Genomic DNA

Francisca Sosa-Jurado; Nora Rosas-Murrieta; Belinda Guzmán-Flores; Cintia Perez Zempoaltecalt; Ana Patricia Sanchez Torres; Leticia Ramirez Rosete; Maribel Bernal-Soto; Luis Márquez-Domínguez; Daniel Meléndez-Mena; Miguel Angel Mendoza Torres; Maria Teresa Lopez Delgado; Julio Reyes-Leyva; Verónica Vallejo-Ruiz

Background The hepatitis B virus (HBV) causes chronic hepatitis, hepatic cirrhosis, and hepatocellular carcinoma. Surface antigen (HBsAg) detection is a definitive test that can confirm HBV infection, while the presence of antibodies against the core protein (anti-HBc) suggests either a previous or ongoing infection or occult hepatitis B infection (OBI). Objectives The aim of the present study was to determine the prevalence of anti-HBc and HBsAg in blood donors. Further, the study aimed to estimate the anti-HBc level at which HBV DNA is detected in putative OBI cases, as well as to search for mutations in the “a” determinant associated with the non-detection of HBsAg in serum. Patients and Methods We conducted a cross-sectional study from 2003–2009. The study included 120,552 blood donors from the state of Puebla, Mexico. Different commercial systems based on microparticles (enzymatic (MEIA) or chemiluminescent (CMIA)) were used to determine the HBsAg and anti-HBc levels. For the detection of HBV DNA, a nested polymerase chain reaction (nested PCR) was used and the genotypes were determined using Sanger sequencing. Results Of the 120,552 blood donors, 1437 (1.19%, 95% CI: 1.12 - 1.26) were reactive to anti-HBc, while 82 (0.066%, 95% CI: 0.053 - 0.079) were reactive to HBsAg. Some 156 plasma samples collected in 2009 from anti-HBc-positive/HBsAg-negative blood donors were submitted for HBV DNA detection in a search for probable OBI. Viral DNA was detected in 27/156 (17.3%, 95% CI: 11.5 - 23.1). Our results show an association between HBV DNA or HBsAg and anti-HBc S/CO levels ≥ 4.0. All DNA samples were identified as genotype H and some “a” determinant mutations were identified, although none corresponded to mutations previously reported to hinder the detection of HBsAg by commercial immunoassays. Conclusions We observed that as the anti-HBc levels increase, there is a higher prevalence of the viral protein HBsAg in blood donors. Samples testing positive for HBV-DNA were seen to exhibit a ten-fold higher presence of anti-HBc S/CO ≥ 4 than those with S/CO ≥ 1 and < 4.0, which highlights the relevance of anti-HBc determination in blood donor samples.


Human Vaccines & Immunotherapeutics | 2016

Hepatitis B surface antibodies in medical students from a public university in Puebla, Mexico

María Elena Cárdenas-Perea; Eduardo Gómez-Conde; Irma Pérez-Contreras; María Alicia Díaz-Orea; José Luís Gándara-Ramírez; Othón Cruz López; Luis Márquez-Domínguez; Francisca Sosa-Jurado

ABSTRACT Although preventable with vaccination, Hepatitis B virus (HBV) infection is a major health concern, with ∼400 million people at risk of developing the chronic form of the disease worldwide. The anti-HBV vaccine consists of a recombinant HBV surface antigen (HBsAg), which induces specific anti-HBs antibodies and confers 95% protection for >20 y. The aim of the present study was to analyze the response to HBV vaccination by measuring anti-HBs antibodies in serum samples from medical students of a public university in Puebla, Mexico. HBV infection markers HBsAg and anti-HBs, were also determined. A total of 201 students were included and vaccination coverage was found at 54%. Overall seropositivity for HBsAg, anti-HBc and anti-HBs determined by ELISA was 0.5%, 1.0% and 47%, respectively. Protective levels of anti-HBs >10 mIU/mL were found in 93.2% of subjects vaccinated with 2 or 3 doses and in 40% of those vaccinated with a single dose; while only 4.8% of unvaccinated subjects were anti-HBs positive. The response to the HBV vaccine was different in each participant, despite similar vaccination scheme. A history of blood transfusion/organ transplant or more than 2 sexual partners was significantly associated with anti-HBc positivity, OR = 399 (p = 0.010) and OR = 19.9 (p = 0.044), respectively. HBV immunization coverage was low in our sample compared with reports from countries with similar HBV prevalence, but anti-HBs in vaccinated individuals were in the expected range. It is important to promote HBV vaccination and awareness among medical students, due to their exposure risk.


Archive | 2014

Molecular Diagnostics as an Indispensable Tool for the Diagnosis of Infectious Diseases of Viral Origin and Global Impact

Nora Rosas-Murrieta; Irma Herrera-Camacho; Lourdes Millan-PerezPeña; Francisca Sosa-Jurado; Gerardo Santos-López; VerónicaVallejo-Ruíz; Julio Reyes-Leyva

Infectious diseases are responsible for a considerable number of deaths in infectious in entire world. Infectious diseases are human diseases caused by viruses, bacteria, parasites, fungi and other microorganisms. Most of them have been controlled by vaccines or antimicrobials. However, some of them still represent global public health problems and are being monitored by the WHO and Center for Disease Control and Prevention. This chapter provides an overview of the applications of molecular methods for infectious diseases caused by viruses (intracellular obligate parasites) of global impact such as Dengue virus, Hepatitis B virus or influenza A virus. The infectious diseases not only represent a potential danger to the life of all human beings but also a significant investment in its detection, treatment and control of their spread. The increase in opportunities of infection by globalization, high rates of mobility among most countries around the world, the patient susceptibility to diseases due to genetic variation in populations [1], the ability of the microorganisms to evade the host immune response has forced the World Health Organization (WHO) to establish better methods of detection, prevention and control of infectious diseases caused by viruses as influenza A virus, coronaviruses, dengue virus, among others [2]. On the other hand, some types of cancer are the result of chronic viral infections caused by human papillomavirus, hepatitis B and C virus. Other infectious diseases are related to the development of neurological disorders caused by the measles virus, or human immunodeficiency virus [3]. In the determination of the etiology


Asian Pacific Journal of Cancer Prevention | 2014

Promoter Polymorphisms of ST3GAL4 and ST6GAL1 Genes and Associations with Risk of Premalignant and Malignant Lesions of the Cervix

Nora Rosas-Murrieta; Raquel Esneidy Hernandez-Pacheco; Irma Zamora; Francisca Sosa-Jurado; Julio Reyes-Leyva; Verónica Vallejo-Ruiz

Sialyltransferase gene expression is altered in several cancers, including examples in the cervix. Transcriptional regulation of the responsible genes depends on different promoters. We aimed to determine the association of single-nucleotide polymorphisms in the B3 promoter of the ST3GAL4 gene and the P1 promoter of the ST6GAL1 gene with cervical premalignant lesions or cervical cancer. A blood sample and/or cervical scrapes were obtained from 104 women with normal cytology, 154 with premalignant lesions and 100 with cervical cancer. We also included 119 blood samples of random donors. The polymorphisms were identified by sequencing from PCR products. For the B3 promoter, a fragment of 506 bp (from nucleotide -408 to +98) was analyzed, and for the P1 promoter a 490 bp (-326 to +164) fragment. The polymorphism analysis showed that at SNP rs10893506, genotypes CC and CT of the ST3GAL4 B3 promoter were associated with the presence of premalignant lesions (OR=2.89; 95%CI 1.72-4.85) and cervical cancer (OR=2.23; 95%CI 1.27-3.91). We detected only one allele of each polymorphism in the ST6GAL1 P1 promoter. We did not detect any genetic variability in the P1 promoter region in our study population. Our results suggest that the rs10893506 polymorphism -22C/T may increase susceptibility to premalignant and malignant lesions of the cervix.

Collaboration


Dive into the Francisca Sosa-Jurado's collaboration.

Top Co-Authors

Avatar

Julio Reyes-Leyva

Mexican Social Security Institute

View shared research outputs
Top Co-Authors

Avatar

Verónica Vallejo-Ruiz

Mexican Social Security Institute

View shared research outputs
Top Co-Authors

Avatar

Daniel Meléndez-Mena

Mexican Social Security Institute

View shared research outputs
Top Co-Authors

Avatar

Luis Márquez-Domínguez

Mexican Social Security Institute

View shared research outputs
Top Co-Authors

Avatar

Nora Rosas-Murrieta

Benemérita Universidad Autónoma de Puebla

View shared research outputs
Top Co-Authors

Avatar

Virginia Sedeño-Monge

Universidad Popular Autónoma del Estado de Puebla

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Abel Cruz-García

Universidad Popular Autónoma del Estado de Puebla

View shared research outputs
Top Co-Authors

Avatar

Adalid Sosa-Palacio

Benemérita Universidad Autónoma de Puebla

View shared research outputs
Top Co-Authors

Avatar

Eduardo Gómez-Conde

Benemérita Universidad Autónoma de Puebla

View shared research outputs
Researchain Logo
Decentralizing Knowledge